TABLE 5.
Summary of epitope mapping
| Group | Immunogen | Contribution to neutralizationa |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| SF162 |
HxB2 |
||||||||
| gp41 | V3 | V1 | D368R | gp41 | V3 | V1 | D368R | ||
| Group A | SF162/YU2 V1 | − (0.0%) | +++ (54.3%) | − (0.0%) | +++++ (84.8%) | ND | ND | ND | ND |
| Group B | SF162/JRFL V1 | − (0.0%) | ++ (36.1%) | − (0.0%) | +++ (48.6%) | − (0.0%) | − (1.0%) | − (0.7%) | + (17.3%) |
| Group C | SF162/89.6 V1 | − (0.0%) | +++ (50.4%) | − (0.0%) | ++++ (77.1%) | − (0.0%) | − (0.0%) | − (0.0%) | + (7.3%) |
| Group D | SF162/HxB2 V1 | − (0.0%) | ++ (25.2%) | − (5.0%) | +++ (54.3%) | − (0.0%) | − (0.5%) | ++ (23.6%) | ++ (21.8%) |
| Group E | V1 scaffold cocktail | − (0.0%) | ++ (33.4%) | − (1.4%) | ++++ (75.9%) | − (0.0%) | − (0.0%) | + (7.9%) | ++ (28.2%) |
| Group F | ΔV1SF162 | − (0.0%) | +++ (49.1%) | − (0.0%) | +++++ (89.8%) | − (0.0%) | − (0.3%) | − (0.0%) | ++ (25.9%) |
| Group G | SF162 gp140 | − (0.0%) | + (5.9%) | ++ (28.4%) | +++++ (99.3%) | − (0.0%) | − (0.0%) | − (0.0%) | +++ (43.8%) |
a
Contribution of Abs directed to a given peptide or recombinant protein to neutralization: −, 0 to 5%; +, 5 to 20%; ++, 20 to 40%; +++, 40 to 60%; ++++, 60 to 80%; +++++, 80 to 100%. The group mean percent contribution to neutralization is given in parentheses. ND, 50% neutralization was not achieved at the highest antibody concentration tested (100 μg/ml) or the lowest plasma dilution tested of (1:20).